# Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy

Study · id `cardio:ct-nct03186742` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03186742](<https://clinicaltrials.gov/study/NCT03186742>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03186742

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.

## Technical summary

Registry record NCT03186742. Randomized; no masking; primary purpose treatment. Start 2014-07-01 (actual); primary completion 2017-01-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 125 participants (enrolled count; ClinicalTrials.gov record NCT03186742, source copy `cardio:ctgov-nct03186742-2017-06-14`, retrieved 2026-10-26)
- Started: 2014-07-01 (actual) (ClinicalTrials.gov record NCT03186742, source copy `cardio:ctgov-nct03186742-2017-06-14`, retrieved 2026-10-26)
- Primary completion: 2017-01-01 (actual) (ClinicalTrials.gov record NCT03186742, source copy `cardio:ctgov-nct03186742-2017-06-14`, retrieved 2026-10-26)
- Completion: 2017-06-01 (actual) (ClinicalTrials.gov record NCT03186742, source copy `cardio:ctgov-nct03186742-2017-06-14`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03186742-2017-06-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Reduction of Left Ventricular Hypertrophy After Eplerenone Therapy
- Condition: Hypertension,Essential
- Condition: Obstructive Sleep Apnea
- Condition: Left Ventricular Hypertrophy
- Intervention (Drug): Eplerenone 50 mg Tab
- Lead sponsor: Poznan University of Medical Sciences
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Poznan University of Medical Sciences (`cardio:org-poznan-university-of-medical-sciences`)

## Provenance

Content hash: 2137d8c2067cd60d4106c969b9d75a656df749fa38d35503c93d5ad5e3f0e369
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
